Ji G, Li Y, Zhang Z, Li H, Sun P
Heliyon. 2024; 10(2):e24667.
PMID: 38312669
PMC: 10834828.
DOI: 10.1016/j.heliyon.2024.e24667.
Pan X, Huang J, Liu S, Shao Y, Xi J, He R
Exp Ther Med. 2023; 26(5):516.
PMID: 37854499
PMC: 10580252.
DOI: 10.3892/etm.2023.12215.
Tan D, Tseng H, Zhong Z, Wang S, Vong C, Wang Y
Int J Mol Sci. 2022; 23(19).
PMID: 36232291
PMC: 9569462.
DOI: 10.3390/ijms231910988.
Speciale A, Muscara C, Molonia M, Cristani M, Cimino F, Saija A
Molecules. 2022; 27(6).
PMID: 35335138
PMC: 8954912.
DOI: 10.3390/molecules27061775.
Stecanella L, Bitencourt A, Vaz G, Quarta E, Silva Junior J, Rossi A
Pharmaceutics. 2021; 13(11).
PMID: 34834206
PMC: 8621092.
DOI: 10.3390/pharmaceutics13111792.
Controlled Release of 18-β-Glycyrrhetinic Acid from Core-Shell Nanoparticles: Effects on Cytotoxicity and Intracellular Concentration in HepG2 Cell Line.
Nocca G, DAvenio G, Amalfitano A, Chronopoulou L, Mordente A, Palocci C
Materials (Basel). 2021; 14(14).
PMID: 34300811
PMC: 8303372.
DOI: 10.3390/ma14143893.
LC/MS-Based Global Metabolomic Identification of Serum Biomarkers Differentiating Hepatocellular Carcinoma from Chronic Hepatitis B and Liver Cirrhosis.
Pan H, Wu Q, Yin Q, Dai Y, Huang Y, Zheng W
ACS Omega. 2021; 6(2):1160-1170.
PMID: 33490775
PMC: 7818305.
DOI: 10.1021/acsomega.0c04259.
Grafting of 18β-Glycyrrhetinic Acid and Sialic Acid onto Chitosan to Produce a New Amphipathic Chitosan Derivative: Synthesis, Characterization, and Cytotoxicity.
Quan W, Kong S, Li S, Liu H, Ouyang Q, Huang Y
Molecules. 2021; 26(2).
PMID: 33467083
PMC: 7829902.
DOI: 10.3390/molecules26020452.
Alginate-Based Platforms for Cancer-Targeted Drug Delivery.
He L, Shang Z, Liu H, Yuan Z
Biomed Res Int. 2020; 2020:1487259.
PMID: 33083451
PMC: 7563048.
DOI: 10.1155/2020/1487259.
Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment.
Zhang J, Li X, Huang L
Adv Drug Deliv Rev. 2020; 154-155:245-273.
PMID: 32473991
PMC: 7704676.
DOI: 10.1016/j.addr.2020.05.006.
Synthesis and characterization of glycyrrhizin-decorated graphene oxide for hepatocyte-targeted delivery.
Wang Z, Gao Y, Xia J, Zhang F, Xia Y, Li Y
C R Chim. 2020; 15(8):708-713.
PMID: 32288748
PMC: 7105227.
DOI: 10.1016/j.crci.2012.05.017.
Dual-Ligand Functionalized Core-Shell Chitosan-Based Nanocarrier for Hepatocellular Carcinoma-Targeted Drug Delivery.
Hefnawy A, Khalil I, Arafa K, Emara M, El-Sherbiny I
Int J Nanomedicine. 2020; 15:821-837.
PMID: 32103939
PMC: 7015065.
DOI: 10.2147/IJN.S240359.
Glycyrrhizin Acid and Glycyrrhetinic Acid Modified Polyethyleneimine for Targeted DNA Delivery to Hepatocellular Carcinoma.
Cao M, Gao Y, Zhan M, Qiu N, Piao Y, Zhou Z
Int J Mol Sci. 2019; 20(20).
PMID: 31614879
PMC: 6829341.
DOI: 10.3390/ijms20205074.
Co-delivery of glycyrrhizin and doxorubicin by alginate nanogel particles attenuates the activation of macrophage and enhances the therapeutic efficacy for hepatocellular carcinoma.
Wang Q, Gao L, Zhu X, Zhang Y, Zhang C, Xu D
Theranostics. 2019; 9(21):6239-6255.
PMID: 31534548
PMC: 6735516.
DOI: 10.7150/thno.35972.
Enhanced Allicin Cytotoxicity on HEPG-2 Cells Using Glycyrrhetinic Acid Surface-Decorated Gelatin Nanoparticles.
Ossama M, Hathout R, Attia D, Mortada N
ACS Omega. 2019; 4(6):11293-11300.
PMID: 31460232
PMC: 6648216.
DOI: 10.1021/acsomega.9b01580.
Traditional Chinese medicine-combination therapies utilizing nanotechnology-based targeted delivery systems: a new strategy for antitumor treatment.
Ma Z, Fan Y, Wu Y, Kebebe D, Zhang B, Lu P
Int J Nanomedicine. 2019; 14:2029-2053.
PMID: 30962686
PMC: 6435121.
DOI: 10.2147/IJN.S197889.
Inhibiting hepatic gluconeogenesis by chitosan lactate nanoparticles containing CRTC2 siRNA targeted by poly(ethylene glycol)-glycyrrhetinic acid.
Rastegari A, Mottaghitalab F, Dinarvand R, Amini M, Arefian E, Gholami M
Drug Deliv Transl Res. 2019; 9(3):694-706.
PMID: 30825078
DOI: 10.1007/s13346-019-00618-1.
Preparation and characterization of norcantharidin liposomes modified with stearyl glycyrrhetinate.
Zhu J, Zhang W, Wang D, Li S, Wu W
Exp Ther Med. 2018; 16(3):1639-1646.
PMID: 30186382
PMC: 6122258.
DOI: 10.3892/etm.2018.6416.
Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
Sun Y, Dai C, Yin M, Lu J, Hu H, Chen D
Int J Nanomedicine. 2018; 13:1621-1632.
PMID: 29588589
PMC: 5862014.
DOI: 10.2147/IJN.S153944.
In vitro and in vivo protein release and anti-ischemia/reperfusion injury properties of bone morphogenetic protein-2-loaded glycyrrhetinic acid-poly(ethylene glycol)-b-poly(l-lysine) nanoparticles.
Shan F, Liu Y, Jiang H, Tong F
Int J Nanomedicine. 2017; 12:7613-7625.
PMID: 29089759
PMC: 5654819.
DOI: 10.2147/IJN.S146546.